JP2008514718A - 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ - Google Patents

置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ Download PDF

Info

Publication number
JP2008514718A
JP2008514718A JP2007534730A JP2007534730A JP2008514718A JP 2008514718 A JP2008514718 A JP 2008514718A JP 2007534730 A JP2007534730 A JP 2007534730A JP 2007534730 A JP2007534730 A JP 2007534730A JP 2008514718 A JP2008514718 A JP 2008514718A
Authority
JP
Japan
Prior art keywords
group
substituted
aryl
amount
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007534730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008514718A5 (enExample
Inventor
エンリコ ピー． ベルトリ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2008514718A publication Critical patent/JP2008514718A/ja
Publication of JP2008514718A5 publication Critical patent/JP2008514718A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007534730A 2004-09-29 2005-09-27 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ Pending JP2008514718A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61416704P 2004-09-29 2004-09-29
PCT/US2005/034812 WO2006039334A1 (en) 2004-09-29 2005-09-27 Combinations of substituted azetidonones and cb1 antagonists

Publications (2)

Publication Number Publication Date
JP2008514718A true JP2008514718A (ja) 2008-05-08
JP2008514718A5 JP2008514718A5 (enExample) 2008-11-06

Family

ID=35539341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007534730A Pending JP2008514718A (ja) 2004-09-29 2005-09-27 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ

Country Status (6)

Country Link
US (1) US20060069080A1 (enExample)
EP (1) EP1807070A1 (enExample)
JP (1) JP2008514718A (enExample)
CA (1) CA2581596A1 (enExample)
MX (1) MX2007003732A (enExample)
WO (1) WO2006039334A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018535192A (ja) * 2015-09-25 2018-11-29 ユニベルシテ ドゥ ナント １，４−ジ−（４−メチルチオフェニル）−３−フタロイルアゼチジン−２−オンおよびその誘導体

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
WO2005061452A1 (en) * 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR060623A1 (es) * 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
FR2902008A1 (fr) * 2006-06-07 2007-12-14 Sanofi Aventis Sa Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie begnine de la prostate
AU2007338625A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
FR2919864A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919863A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
EP2995317A1 (en) 2010-05-26 2016-03-16 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EP2771003B1 (en) 2011-10-28 2017-04-19 Lumena Pharmaceuticals LLC Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
MX2015013193A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores del reciclaje de acidos biliares para el tratamiento de colangitis esclerosante primaria y enfermedad inflamatoria intestinal.
CA2907214A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
WO2020167981A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for increasing growth in pediatric subjects having cholestatic liver disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509989A (ja) * 1993-09-21 1996-10-22 シェーリング コーポレイション 低コレステロール血症薬剤として有用なヒドロキシ置換アゼチジノン化合物
JP2001501971A (ja) * 1997-01-28 2001-02-13 サノフィ−サンテラボ 中枢性カンナビノイドレセプターアンタゴニストの欲求（ａｐｐｅｔｅｎｃｅ）を制御するための使用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4820850A (en) * 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
HUT67341A (en) * 1991-07-23 1995-03-28 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same and process for the production thereof
US5561227A (en) * 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5668990A (en) * 1995-03-30 1997-09-16 Pitney Bowes Inc. Apparatus and method for generating 100% United States Postal Service bar coded lists
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
ES2248901T3 (es) * 1997-05-14 2006-03-16 Atherogenics, Inc. Monoesteres de probucol para el tratamiento de trastornos cardiovasculares e inflamatorios.
HN1998000027A (es) * 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
IL151452A0 (en) * 2000-03-23 2003-04-10 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PE20020718A1 (es) * 2000-12-20 2002-08-09 Schering Corp 2-azetidinonas sustituidas con azucares utiles como agentes hipocolesterolemicos
WO2002050027A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
EP1345924B1 (de) * 2000-12-21 2006-08-30 Sanofi-Aventis Deutschland GmbH Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
DE60206365T2 (de) * 2001-03-28 2006-07-06 Schering Corporation, Kenilworth Verfahren für die enantioselektive synthese von azetidinon-zwischenprodukten
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
WO2004004655A2 (en) * 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
AU2003259131A1 (en) * 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7816357B2 (en) * 2003-12-19 2010-10-19 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509989A (ja) * 1993-09-21 1996-10-22 シェーリング コーポレイション 低コレステロール血症薬剤として有用なヒドロキシ置換アゼチジノン化合物
JP2001501971A (ja) * 1997-01-28 2001-02-13 サノフィ−サンテラボ 中枢性カンナビノイドレセプターアンタゴニストの欲求（ａｐｐｅｔｅｎｃｅ）を制御するための使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018535192A (ja) * 2015-09-25 2018-11-29 ユニベルシテ ドゥ ナント １，４−ジ−（４−メチルチオフェニル）−３−フタロイルアゼチジン−２−オンおよびその誘導体

Also Published As

Publication number Publication date
EP1807070A1 (en) 2007-07-18
CA2581596A1 (en) 2006-04-13
MX2007003732A (es) 2007-04-23
WO2006039334A1 (en) 2006-04-13
US20060069080A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
JP2008514718A (ja) 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
JP4777602B2 (ja) ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置
JP4711600B2 (ja) シトステロール血症の処置のための置換アゼチジノン化合物の使用
JP4395370B2 (ja) ステロール吸収阻害剤を使用して血管炎症を治療または予防する方法
DE60221798T2 (de) Kombinationen von gallensäure sequestriermitteln und hemmern der sterol absorption zur behandlung von kardiovaskulären indikationen
JP2004517916A (ja) ニコチン酸およびその誘導体ならびにステロール吸収阻害剤の併用、および血管適応症の治療
JP2005504091A (ja) ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
AU2002336609A1 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
CN1915429B (zh) 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
RU2483724C2 (ru) Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110809